Gelesis Holdings Inc
Change company Symbol lookup
Select an option...
GLS Gelesis Holdings Inc
CAC Camden National Corp
RE Everest Re Group Ltd
URRNF Twenty Seven Co Ltd
TWLV Twelve Seas Investment Co II
FLO Flowers Foods Inc
CAJ Canon Inc
WPC WP Carey Inc
PPT Putnam Premier Income Trust
GME GameStop Corp
Go

Company profile

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. It focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate include GS200, provides additional potential health benefits in prediabetics and type two diabetics. It is also developing GS300, treatment for NAFLD and NASH and GS500, for the treatment of FC.

Closing Price
$4.73
Day's Change
-0.53 (-10.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.47
Day's Low
4.71
Volume
(Light)
Volume:
116,965

10-day average volume:
224,264
116,965

Company Profile

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. It focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate include GS200, provides additional potential health benefits in prediabetics and type two diabetics. It is also developing GS300, treatment for NAFLD and NASH and GS500, for the treatment of FC.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
0.84x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2022
Current Month
508.7K
Previous Month
267.8K
Percent of Float
3.48%
Days to Cover
0.9699 Days

Share Information

GLS is in a share class of common stock
Float
14.8M
Shares Outstanding
34.5M
Institutions Holding Shares
90
137.86%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.